MX2010011845A - Agonistas del receptor y2 y/o y4 de larga accion. - Google Patents
Agonistas del receptor y2 y/o y4 de larga accion.Info
- Publication number
- MX2010011845A MX2010011845A MX2010011845A MX2010011845A MX2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A
- Authority
- MX
- Mexico
- Prior art keywords
- ethoxy
- seq
- carboxy
- acid
- acetyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08156360 | 2008-05-16 | ||
| EP09154461 | 2009-03-05 | ||
| PCT/EP2009/055989 WO2009138511A1 (en) | 2008-05-16 | 2009-05-18 | Long-acting y2 and/or y4 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010011845A true MX2010011845A (es) | 2010-11-22 |
Family
ID=40934036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010011845A MX2010011845A (es) | 2008-05-16 | 2009-05-18 | Agonistas del receptor y2 y/o y4 de larga accion. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110275559A1 (enExample) |
| EP (1) | EP2279204A1 (enExample) |
| JP (1) | JP2011520847A (enExample) |
| KR (1) | KR20110017874A (enExample) |
| CN (1) | CN102027007A (enExample) |
| AU (1) | AU2009248041B2 (enExample) |
| BR (1) | BRPI0912615A2 (enExample) |
| CA (1) | CA2723855A1 (enExample) |
| IL (1) | IL208836A0 (enExample) |
| MX (1) | MX2010011845A (enExample) |
| RU (1) | RU2504550C2 (enExample) |
| WO (1) | WO2009138511A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9260500B2 (en) | 2009-07-02 | 2016-02-16 | Takeda Pharmaceutical Company Limited | Peptide and use thereof |
| EP2477643A1 (en) * | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| EP2498800A1 (en) * | 2009-11-13 | 2012-09-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| GB201001333D0 (en) * | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| EP2600887A4 (en) | 2010-07-09 | 2014-01-22 | Amylin Pharmaceuticals Llc | MICROCRYSTALLINE Y RECEPTOR AGONISTS |
| MX345501B (es) | 2010-12-16 | 2017-02-02 | Novo Nordisk As | Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico. |
| EP2827885B1 (en) | 2012-03-22 | 2018-08-15 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| SMT201800492T1 (it) | 2013-05-02 | 2018-11-09 | Novo Nordisk As | Dosaggio orale di composti di glp-1 |
| EP2842965A1 (en) | 2013-09-03 | 2015-03-04 | Gubra ApS | Neuromedin U analogs comprising serum albumin binding amino acid residue |
| WO2015073878A1 (en) * | 2013-11-15 | 2015-05-21 | Ur Diet, Llc | Real-time satiety biofeedback |
| AU2014350197B2 (en) | 2013-11-15 | 2018-10-04 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| PT3068421T (pt) * | 2013-11-15 | 2019-07-11 | Novo Nordisk As | Compostos de pyy eletivo e usos dos mesmos |
| EP3068795B1 (en) * | 2013-11-15 | 2019-03-06 | Novo Nordisk A/S | Hpyy(1-36) having a beta-homoarginine substitution at position 35 |
| US20240100450A9 (en) * | 2014-01-17 | 2024-03-28 | Repligen Corporation | Sterilizing chromatography columns |
| JP6653654B2 (ja) | 2014-01-17 | 2020-02-26 | レプリゲン・コーポレイションRepligen Corporation | クロマトグラフィーカラムの滅菌 |
| CN114805527A (zh) * | 2014-05-21 | 2022-07-29 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
| AU2016275735B2 (en) | 2015-06-12 | 2020-02-06 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| EP4299118A3 (en) | 2018-02-02 | 2024-04-10 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| TWI749381B (zh) | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| GB201908426D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Appetite suppressing compounds |
| US11739134B2 (en) * | 2020-04-17 | 2023-08-29 | Intarcia Therapeutics, Inc. | Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use |
| AU2022263996A1 (en) | 2021-04-27 | 2023-11-02 | Aardvark Therapeutics, Inc. | Combination of bitter receptor agonist and gut-signaling compound |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2431800C (en) * | 2000-12-14 | 2014-07-08 | Amylin Pharmaceuticals, Inc. | Peptide yy and peptide yy agonists for treatment of metabolic disorders |
| CA2539253A1 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| US8603969B2 (en) * | 2004-02-11 | 2013-12-10 | Amylin Pharmaceuticals, Llc | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| ATE519495T1 (de) * | 2004-03-17 | 2011-08-15 | 7Tm Pharma As | Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe |
| ES2542228T3 (es) * | 2004-07-08 | 2015-08-03 | Novo Nordisk A/S | Marcas de prolongación polipeptídica que comprenden un resto de tetrazol |
| CN101222942A (zh) * | 2005-07-18 | 2008-07-16 | 诺沃-诺迪斯克有限公司 | 用于治疗肥胖的肽 |
-
2009
- 2009-05-18 RU RU2010149474/04A patent/RU2504550C2/ru not_active IP Right Cessation
- 2009-05-18 KR KR1020107027495A patent/KR20110017874A/ko not_active Withdrawn
- 2009-05-18 CA CA2723855A patent/CA2723855A1/en not_active Withdrawn
- 2009-05-18 EP EP09745843A patent/EP2279204A1/en not_active Withdrawn
- 2009-05-18 BR BRPI0912615A patent/BRPI0912615A2/pt not_active Application Discontinuation
- 2009-05-18 MX MX2010011845A patent/MX2010011845A/es not_active Application Discontinuation
- 2009-05-18 AU AU2009248041A patent/AU2009248041B2/en not_active Ceased
- 2009-05-18 JP JP2011508945A patent/JP2011520847A/ja not_active Withdrawn
- 2009-05-18 WO PCT/EP2009/055989 patent/WO2009138511A1/en not_active Ceased
- 2009-05-18 CN CN2009801173043A patent/CN102027007A/zh not_active Withdrawn
- 2009-05-18 US US12/993,015 patent/US20110275559A1/en not_active Abandoned
-
2010
- 2010-10-20 IL IL208836A patent/IL208836A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009248041A1 (en) | 2009-11-19 |
| IL208836A0 (en) | 2011-01-31 |
| RU2504550C2 (ru) | 2014-01-20 |
| AU2009248041B2 (en) | 2013-10-03 |
| WO2009138511A1 (en) | 2009-11-19 |
| CA2723855A1 (en) | 2009-11-19 |
| BRPI0912615A2 (pt) | 2016-01-26 |
| EP2279204A1 (en) | 2011-02-02 |
| JP2011520847A (ja) | 2011-07-21 |
| CN102027007A (zh) | 2011-04-20 |
| KR20110017874A (ko) | 2011-02-22 |
| US20110275559A1 (en) | 2011-11-10 |
| RU2010149474A (ru) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010011845A (es) | Agonistas del receptor y2 y/o y4 de larga accion. | |
| JP5755398B2 (ja) | 伸長されたglp−1化合物 | |
| JP4585037B2 (ja) | アシル化glp−1化合物 | |
| ES2672770T3 (es) | Derivados del péptido-1 similar al glucagón y su uso farmacéutico | |
| EP2190873B1 (en) | Truncated glp-1 derivatives and their therapeutical use | |
| AU2010203063B2 (en) | Albumin-binding derivatives of therapeutic peptides | |
| KR102505628B1 (ko) | 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제 | |
| US20130040877A1 (en) | Long-acting y2 receptor agonists | |
| EP2190460A1 (en) | Peptides derivatized with a-b-c-d- and their therapeutical use | |
| JP2007537142A (ja) | アルブミン様物質に結合した新規のglp−1類似物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |